Prospective investigation of polyomavirus infection and the risk of adult glioma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 05 2021
05 05 2021
Historique:
received:
15
10
2020
accepted:
16
04
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Glioma is an aggressive primary tumor of the brain with a poorly understood etiology. We studied the association of 4 human polyomaviruses (HPyV)-JC virus (JCV), BK virus (BKV), human polyomavirus 6 (HPyV6), and Merkel cell polyomavirus (MCPyV) with glioma risk within the Cancer Prevention Study II in the US (CPS-II) and the Janus Serum Bank in Norway. Cohort participants subsequently diagnosed with glioma from the CPS-II (n = 37) and Janus Serum Bank (n = 323), a median of 6.9 and 15.4 years after blood collection, respectively, were matched to individual controls on age, sex, and date of blood draw. Serum antibodies to the major viral capsid protein (VP1) were used to establish infection history for each polyomavirus. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. In the Janus Serum Bank, MCPyV infection was associated with a higher risk of glioma overall (OR: 1.56; 95% CI 1.10, 2.19). A modest, nonsignificant positive association with MCPyV infection was also observed in CPS-II (OR: 1.29; 95% CI 0.54, 3.08). In both cohorts, glioma risk was not significantly related to infection with JCV, BKV or HPyV6. The present study suggests that MCPyV infection may increase glioma risk.
Identifiants
pubmed: 33953301
doi: 10.1038/s41598-021-89133-3
pii: 10.1038/s41598-021-89133-3
pmc: PMC8100283
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9642Références
Obesity (Silver Spring). 2015 Mar;23(3):512-8
pubmed: 25612251
Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):460-3
pubmed: 12750243
Brain Res Brain Res Rev. 2005 Dec 1;50(1):69-85
pubmed: 15982744
Cancer Causes Control. 2014 Aug;25(8):1007-13
pubmed: 24890803
J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50
pubmed: 17925535
Cancer Res. 2012 Jul 15;72(14):3445-50
pubmed: 22761333
Br J Cancer. 2014 Apr 2;110(7):1825-33
pubmed: 24595001
Clin Biochem. 2015 Apr;48(6):364-9
pubmed: 25523301
Viruses. 2011 Apr;3(4):398-422
pubmed: 21994739
Neuro Oncol. 2012 Nov;14(11):1316-24
pubmed: 22952197
Acta Neuropathol Commun. 2016 Jul 11;4(1):71
pubmed: 27402152
J Gen Virol. 2010 Jul;91(Pt 7):1849-53
pubmed: 20219899
Cancer. 2002 Jan 15;94(2):500-11
pubmed: 11900235
Infect Agent Cancer. 2018 Apr 5;13:12
pubmed: 29632550
PLoS Pathog. 2009 Mar;5(3):e1000363
pubmed: 19325891
PLoS One. 2018 Oct 23;13(10):e0206273
pubmed: 30352098
Nat Rev Microbiol. 2013 Apr;11(4):264-76
pubmed: 23474680
Int J Cancer. 2007 Jun 1;120(11):2459-65
pubmed: 17315193
Int Immunopharmacol. 2001 Sep;1(9-10):1651-67
pubmed: 11562058
Front Oncol. 2019 Aug 06;9:713
pubmed: 31448229
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
PLoS One. 2013 Nov 21;8(11):e81078
pubmed: 24278381
J Neuroimmunol. 1998 Mar 15;83(1-2):148-56
pubmed: 9610683
PLoS One. 2017 Jun 8;12(6):e0178705
pubmed: 28594935
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Psychoneuroendocrinology. 1998 Feb;23(2):175-87
pubmed: 9621397
Science. 2008 Feb 22;319(5866):1096-100
pubmed: 18202256
Allergy. 2011 Nov;66(11):1434-41
pubmed: 21726235
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
Proc Nutr Soc. 2012 May;71(2):332-8
pubmed: 22429824
Nat Immunol. 2013 May;14(5):428-36
pubmed: 23598398
Lancet. 1990 Jun 30;335(8705):1561-3
pubmed: 1972490
J Virol. 2014 Jan;88(1):774
pubmed: 24353289
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
Lancet. 1971 Jun 19;1(7712):1257-60
pubmed: 4104715
Nat Rev Immunol. 2007 Feb;7(2):161-7
pubmed: 17220915
Curr Infect Dis Rep. 2017 Feb;19(2):5
pubmed: 28233187
J Glob Health. 2020 Jun;10(1):010405
pubmed: 32257153
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Clin Vaccine Immunol. 2013 Mar;20(3):363-8
pubmed: 23302741
Am J Epidemiol. 2016 Jan 1;183(1):61-9
pubmed: 26667254
J Virol. 2013 Aug;87(16):8916-26
pubmed: 23740984
Am J Epidemiol. 2005 May 15;161(10):929-38
pubmed: 15870157
J Virol. 2014 Nov;88(21):12816-24
pubmed: 25165109
Cancer Med. 2016 Jun;5(6):1352-8
pubmed: 26972449
Nat Immunol. 2018 Jan;19(1):10-19
pubmed: 29242543
Semin Liver Dis. 2013 May;33(2):147-56
pubmed: 23749671
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Nat Rev Immunol. 2002 May;2(5):372-7
pubmed: 12033743
Ann Oncol. 2019 Aug 1;30(8):1335-1343
pubmed: 31185496
Neurooncol Pract. 2016 Mar;3(1):10-16
pubmed: 26941959
Lancet Neurol. 2018 May;17(5):467-480
pubmed: 29656742
Br J Dermatol. 2019 Jun;180(6):1302-1311
pubmed: 30585627
J Natl Cancer Inst. 2012 Aug 22;104(16):1251-9
pubmed: 22855780
Am J Epidemiol. 1997 Apr 1;145(7):594-7
pubmed: 9098175
J Med Virol. 2016 Jul;88(7):1254-61
pubmed: 26630080
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1337-1344
pubmed: 28483968
Nat Genet. 2017 May;49(5):789-794
pubmed: 28346443
Neuro Oncol. 2016 Jan;18(1):16-26
pubmed: 26188014
J Natl Cancer Inst. 2011 May 4;103(9):714-36
pubmed: 21454908
J Natl Cancer Inst. 2011 Nov 2;103(21):1588-95
pubmed: 22010181
Emerg Infect Dis. 2013 Jan;19(1):77-84
pubmed: 23260029
Cancer Res. 2010 Nov 1;70(21):8388-97
pubmed: 20959478
J Clin Virol. 2018 Apr;101:34-37
pubmed: 29414185
Lancet. 1971 Jun 19;1(7712):1253-7
pubmed: 4104714
Int J Epidemiol. 2017 Apr 1;46(2):403-404g
pubmed: 27063606
Oncogene. 2005 Nov 21;24(52):7656-72
pubmed: 16299527
J Am Acad Dermatol. 2018 Mar;78(3):433-442
pubmed: 29229574
Int J Epidemiol. 2012 Aug;41(4):1075-85
pubmed: 22933650
Acta Virol. 2017;61(4):393-400
pubmed: 29186956